IVVD Doubled on Clinical Trial Results
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. Earnings in 48 days. Avg 30D Vol at 24.67M Current Vol at 74.70M
Can this break and retest $2.35? If it does analyst have targets as high as $10. GL!
Can this break and retest $2.35? If it does analyst have targets as high as $10. GL!
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.